

Michael G Nanna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/356584/publications.pdf>

Version: 2024-02-01

36
papers

833
citations

567281

15
h-index

501196

28
g-index

36
all docs

36
docs citations

36
times ranked

1255
citing authors

#	ARTICLE	IF	CITATIONS
1	The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. <i>American Heart Journal</i> , 2022, 245, 136-148.	2.7	13
2	Are risk factors necessary for pretest probability assessment of coronary artery disease? A patient similarity network analysis of the PROMISE trial. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 397-403.	1.3	5
3	High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1802-1813.	2.8	52
4	An age-old dilemma: Defining the optimal revascularization approach in older adults. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2205-2208.	2.6	0
5	Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease. <i>JAMA Network Open</i> , 2022, 5, e2218189.	5.9	18
6	Presentation, Treatment, and Outcomes of the Oldest-Old Patients with Acute Myocardial Infarction: The SILVER-AMI Study. <i>American Journal of Medicine</i> , 2021, 134, 95-103.	1.5	7
7	Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?. <i>American Journal of Cardiology</i> , 2021, 142, 83-90.	1.6	0
8	The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease. <i>Atherosclerosis</i> , 2021, 321, 1-7.	0.8	1
9	Precision medicine gets an ASSIST in diagnostic testing. <i>European Heart Journal</i> , 2021, 42, 2549-2551.	2.2	1
10	Rise of the Machines: Where Virtual Processing Meets Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1504-1506.	1.7	0
11	Estimating the real-world performance of the PROMISE minimal-risk tool. <i>American Heart Journal</i> , 2021, 239, 100-109.	2.7	4
12	Cholesterol Lowering and Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 268-270.	2.8	0
13	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1550-1563.	2.8	16
14	Moving the Field Forward: Untangling the Impact of Frailty on Patients With Advanced Heart Failure and on Prognosticating Outcomes. <i>Journal of Cardiac Failure</i> , 2021, , .	1.7	0
15	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E102-E109.	1.7	10
16	The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. <i>Journal of General Internal Medicine</i> , 2020, 35, 1701-1708.	2.6	31
17	Translating the Secondary Prevention Therapeutic Boom Into Action. <i>JAMA Cardiology</i> , 2020, 5, 215.	6.1	1
18	Age, knowledge, preferences, and risk tolerance for invasive cardiac care. <i>American Heart Journal</i> , 2020, 219, 99-108.	2.7	16

#	ARTICLE	IF	CITATIONS
19	Age-Related Differences in the Noninvasive Evaluation for Possible Coronary Artery Disease. <i>JAMA Cardiology</i> , 2020, 5, 193.	6.1	24
20	Predicting 6-Month Mortality for Older Adults Hospitalized With Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2020, 172, 12.	3.9	26
21	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 653-664.	2.8	39
22	Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. <i>JAMA Internal Medicine</i> , 2020, 180, 1531.	5.1	23
23	Teaching Old Treatments New Tricks. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009725.	3.9	0
24	Racial Differences in Long-Term Cardiovascular Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1596-1598.	2.9	9
25	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020, 75, 835-837.	2.8	1
26	Weight change in heart failure inpatients not associated with 30-day readmission. <i>Future Cardiology</i> , 2020, 16, 289-296.	1.2	0
27	The Association Between Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2560-2567.	2.6	26
28	Sex Differences in the Use of Statins in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005562.	2.2	155
29	Sex-Based Differences in Presentation, Treatment, and Complications Among Older Adults Hospitalized for Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005691.	2.2	44
30	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2019, 214, 113-124.	2.7	17
31	Thirty-Day Readmission Risk Model for Older Adults Hospitalized With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005320.	2.2	40
32	Long-Term Cognitive Decline After Newly Diagnosed Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004476.	3.9	82
33	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004249.	2.2	24
34	Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	49
35	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. <i>JAMA Cardiology</i> , 2018, 3, 739.	6.1	94
36	Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 303-315.	2.1	5